The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

Mergers & Acquisitions•26 June 2026•

1 min read

Neuphoria Confirms Merger Talks with Scancell in Biotech Sector

Key Facts

1Neuphoria Therapeutics confirmed it is in talks with Scancell Holdings about a possible combination.

In a move reflecting continued M&A activity in the biotech sector, Neuphoria Therapeutics confirmed it is in talks with Scancell Holdings regarding a possible combination. According to reports, neither company has disclosed financial terms or deal details yet, indicating that discussions remain in early stages.

Neuphoria shares (NEUP) closed at $4.35 on June 25, 2026, per market data, after trading between $4.35 and $4.49 during the session. The announcement comes amid a period of heightened merger and acquisition activity in biotechnology, as companies seek to strengthen pipelines and expand operations.

Investors are now focused on any further developments regarding the deal, including potential regulatory approvals and merger terms. With no official statement from Scancell so far, the stock remains under watch, with possible price movements as talks progress.